BioTuesdays

Category - Feature

Feature

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating...

November 19, 2013
Feature

DARA’s sales team goes on a Mission

A new sales and marketing venture with a unit of Mission Pharmacal gives DARA BioSciences (NASDAQ:DARA) a formidable leg up in the oncology supportive care sector to address ongoing areas of medical need. A 20-person...

November 12, 2013
Feature

In conversation with Paul Lem

As CEO and co-founder of closely-held Spartan Bioscience, Dr. Paul Lem has a diverse background in clinical medicine, molecular biology research and as a biotech entrepreneur. Prior to co-founding Spartan in 2005, he...

November 5, 2013
Feature

NeoStem completing enrollment in heart trial

NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data readout six-to...

October 29, 2013
Feature

Heat Biologics readies proof-of-concept studies

After a successful $27-million IPO in the summer, Heat Biologics (NASDAQ:HTBX) plans to begin two proof-of-concept trials later this year of its platform to transform living cancer cells into pumps that continually...

October 22, 2013
Feature

CytRx awaiting soft tissue sarcoma data in December

What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when it plans to...

October 15, 2013
Feature

Aethlon readies U.S. study of the Hemopurifier

Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility study to...

October 1, 2013
Feature

In conversation with Kelly Close

As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as her personal experience...

September 24, 2013
Feature

diaDexus awaiting GSK’s darapladib pivotal results

Positive data from GlaxoSmithKline’s two pivotal trials of its darapladib cardiovascular drug could provide a huge boost to the utilization of diaDexus’ (OTCQB:DDXS) PLAC test, which is being used on patients in the...

September 17, 2013
Feature

In conversation with Zoe Barry

As founder and CEO of ZappRx, a consumer engagement company focused on improving the electronic prescription process, Zoe Barry began her career as an analyst at hedge fund, Dawson Capital, in New York, where her role...

September 10, 2013